Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Chimeric Antigen Receptor (CAR) T Cells”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Early research (Phase 1)UnknownNCT05523661
What this trial is testing

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

Who this might be right for
Ph Positive ALLCAR-T CellDasatinib
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 15
Early research (Phase 1)UnknownNCT03463928
What this trial is testing

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

Who this might be right for
B Cell Leukemia
Chinese PLA General Hospital 10
Early research (Phase 1)Looking for participantsNCT06285279
What this trial is testing

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Who this might be right for
Lupus NephritisANCA-associated VasculitisMembranous Nephropathy - PLA2R Induced+1 more
Nanjing University School of Medicine 24
Very early researchUnknownNCT05225831
What this trial is testing

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
CD19+ and CD 22+ B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06735495
What this trial is testing

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Testing effectiveness (Phase 2)UnknownNCT04553393
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Who this might be right for
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital 80
Early research (Phase 1)UnknownNCT03879382
What this trial is testing

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

Who this might be right for
POMES SyndromeRelapsed and Refractory POMES Syndrome
Hrain Biotechnology Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT06081478
What this trial is testing

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-cell LymphomaDiffuse Large B Cell Lymphoma
Beijing Tongren Hospital 100
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Testing effectiveness (Phase 2)Looking for participantsNCT06503094
What this trial is testing

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)UnknownNCT04303520
What this trial is testing

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Who this might be right for
CD19-positive ALL
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Not applicableStudy completedNCT06415656
What this trial is testing

VitalTraq for the Detection of CRS

Who this might be right for
Hematologic Malignancy
Duke University 32
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Early research (Phase 1)WithdrawnNCT03605238
What this trial is testing

Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Neuromyelitis Optica Spectrum Disorder
Chinese PLA General Hospital
Early research (Phase 1)Looking for participantsNCT06559189
What this trial is testing

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver 53
Testing effectiveness (Phase 2)Looking for participantsNCT06880913
What this trial is testing

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Who this might be right for
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05800977
What this trial is testing

C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd. 112
Not applicableLooking for participantsNCT07309497
What this trial is testing

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich 208
Load More Results